Skip to main content

Table 7 Progression-free survival (PFS) and overall survival (OS)

From: Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

 

Dose level

 
 

1

2

3

Total

Number of patients

4 (100%)

13 (100%)

7 (100%)

24 (100%)

PFS (months)

    

  Median (95% CI)

2.25 (1.4, 8.1)

6.5 (2.5, n.a.)

13.5 (2.3, 14.4)

6.5 (2.3, 13.3)

OS (months)

    

  Median (95% CI)

8.5 (5.6, 12.0)

29.5 (4.8, n.a.)

22.1 (16.3, 22.1)

16.3 (7.6, 29.5)